Head-to-head evidence
Omarigliptin vs Sitagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Omarigliptin · Marizev
Developed by Merck & Co.
NCT01682759 · Phase 3 · completed
This trial randomized 751 patients in double-blind fashion to omarigliptin or an active comparator (glimepiride), both added to background metformin, for 54 weeks. The primary endpoint was change in HbA1c (a regulator-accepted, disease-defining measure for diabetes), and the prespecified non-inferiority margin of 0.35% was met: the upper bound of the 95% confidence interval for the treatment difference (0.30%) fell within the margin. The trial was adequately sized, properly blinded, and its primary comparison succeeded as designed, making this strong controlled evidence for omarigliptin, even though omarigliptin showed a numerically smaller HbA1c reduction than glimepiride.
Sitagliptin · Januvia
Marketed by Merck & Co.
NCT00087516 · Phase 3 · completed
The trial randomized 741 participants to double-blind sitagliptin or placebo groups, providing a substantial controlled comparison. The primary endpoint, change in A1C at week 24, was statistically favorable for both sitagliptin doses (p<0.001), but A1C is a surrogate endpoint, so the evidence is rated moderate rather than strong.
Next expected readout: October 2026 · NCT07711171 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Omarigliptin's landscape · Sitagliptin's landscape